Significant reductions were seen in MACE, renal disease progression in patients with high CV risk taking canagliflozin.
A large international study found people with highest blood levels of linoleic acid were 35% less likely to develop T2DM than those with the lowest levels.
Can you sort out diabetes facts from fiction? The latest diabetes statistics from the CDC may surprise you.
This tip and 4 others can help you deliver a message that resonates.
At-a-glance: SGLT2 inhibitors, GLP-1 agonists, insulin vs insulin, and more—a look at what’s new, what’s next.
A new open-label randomized controlled trial finds use of CGM in T1DM pregnancies may improve neonatal outcomes.
A new study evaluates the impact of ethnicity on skin autoflourescence used to measure accumulation of atherogenic glycated proteins.
What about those patients who fall into the "gray zone"?
The early impact of carbohydrate restriction was clinically significant but not sustained, according to authors of a new meta-analysis.
Timing appears to be nearly everything when it comes to the impact of respiratory infection on autoantibody seroconversion in infants at risk for tpye 1 diabetes.
You can attempt to renegotiate. Sometimes it works . . . but sometimes it doesn’t.
The extended-release GLP-1 agonist was added to usual care in T2DM patients with and without previous cardiac disease.
At-a-Glance: Studies you may find of interest look at AFib in T1DM, new fracture risk data, obesity outcomes, and more.
In a new study, an intensive lifestyle intervention did not markedly decrease A1c but had significant impact on need for medication.
A new meta-analysis finds that routine intake of artificial sweeteners is linked to the opposite of the intended effect.